Ronan Flippot, Tugce Telli, Maud Velev, Aude Fléchon, Manon De Vries-Brilland, Léa Turpin, Andries Bergman, Fabio Turco, Hakim Mahammedi, Wolfgang P Fendler, Anne-Laure Giraudet, Quentin Josset, Françoise Montravers, Wouter Vogel, Silke Gillessen, Simona Berardi Vilei, Ken Herrmann, David Kryza, Gaetano Paone, Boris Hadaschik, Charles Merlin, Pierre-Alban Dufour, Alice Bernard-Tessier, Natacha Naoun, Anna Patrikidou, Camilo Garcia, Stéphanie Foulon, Arnaud Pagès, Karim Fizazi
BACKGROUND: Both cabazitaxel and lutetium-177 prostate-specific membrane antigen (Lu-PSMA) improve survival in metastatic castration-resistant prostate cancer (mCRPC) after an androgen receptor pathway inhibitor and docetaxel, but there are limited data regarding Lu-PSMA activity after cabazitaxel. OBJECTIVE: To assess the activity of Lu-PSMA and determinants of outcomes after cabazitaxel in mCRPC. DESIGN, SETTING, AND PARTICIPANTS: A retrospective analysis was conducted of consecutive mCRPC patients from eight European centers treated with Lu-PSMA after cabazitaxel...
April 24, 2024: European Urology Oncology